Journal: Acta Pharmaceutica Sinica. B

Article Title: Targeting FAP α -positive hepatic stellate cells ameliorates the formation of pre-metastatic niche

doi: 10.1016/j.apsb.2026.04.018

Figure Lengend Snippet: FAP α + HSCs upregulate NF- κ B/NLRP3/caspase-1/IL-18 signaling pathway. (A) KEGG analysis of the Top100 upregulated genes in LX-2 FAP cells. (B) GO analysis of paracancerous and healthy HSCs from scRNA sequencing. (C) Western blotting analysis of FAP α , NF κ B-p65, p- NF κ B-p65, NLRP3, pro caspase-1, caspase-1 P 20, IL-18 in LX-2 FAP cells with or without SP-13786 ( n = 3). (D) Immunocytochemistry of NLRP3 in LX-2 FAP cells with or without SP-13786 ( n = 3). Scale bar, 10 μm. (E) ELISA analysis of IL-18 concentration in LX-2 FAP cells ( n = 3). (F) ELISA analysis of IL-18 in the peripheral blood of Fap fl / fl or Fap ΔGfap mice with MC38-luc or Panc02-luc injection ( n = 5). (G, H) Immunofluorescence staining of NLRP3, caspase-1, or IL-18 (green) in α SMA + HSCs (gray) that adhered to the CD31 + sinusoidal blood vessels (red) in the PMN of CRC or pancreatic cancer ( n = 5). Scale bar, 10 μm. Data are presented as mean ± SEM. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 (one-way ANOVA with Tukey's post hoc comparison in D; two-tailed unpaired t -test in E–H).

Article Snippet: LX-2 FAP cells were treated with a FAP α inhibitor SP-13786 (50 μmol/L, T7890, TargetMol, Shanghai, China) for 30 min. Gene knockdown in LX-2 Vector and LX-2 FAP cells was achieved by infection with shRNA plasmids or transfection with siRNAs, using corresponding negative controls as references.

Techniques: Analysis, Sequencing, Western Blot, Immunocytochemistry, Enzyme-linked Immunosorbent Assay, Concentration Assay, Injection, Immunofluorescence, Staining, Comparison, Two Tailed Test, Significance Assay

Journal: Bioconjugate Chemistry

Article Title: FAP-Targeted Fluorescent Imaging Agents to Study Cancer-Associated Fibroblasts In Vivo

doi: 10.1021/acs.bioconjchem.4c00426

Figure Lengend Snippet: Synthesis of FTF imaging agents. Six different NHS ester activated fluorophores were reacted with FAP-IN-2 precursor, in a single-step synthesis. Yields for various conjugates ranged between 20 and 80% depending on reaction. The lead compounds, FTF-TAMRA and FTF-BODIPY-TMR, were synthesized at ∼80% yield. Compounds were purified via HPLC and lyophilized to yield a dry powder and resuspended in stocks of dimethyl sulfoxide (DMSO) to be further diluted for subsequent use.

Article Snippet: Fibroblast activation protein inhibitors FAP-In-2 TFA (purity: 99.92%) and FAPi-4 were procured from MedChemExpress.

Techniques: Imaging, Synthesized, Purification